Virtual Library
Start Your Search
Ticiana Leal
Author of
-
+
IASLC Pre-Conference School of Thoracic Oncology (ID 1)
- Event: LALCA 2019
- Type: Invited Speaker Session
- Track:
- Presentations: 2
- Moderators:
- Coordinates: 10/17/2019, 09:00 - 15:30, Castillo A 1-2
-
+
PC1.06 - Conducting and Attracting Clinical Trials in Your Region: Mission Impossible? (ID 6)
09:00 - 15:30 | Author(s): Ticiana Leal
- Abstract
Abstract not provided
-
+
PC1.11 - Updating Your CV and Personal Statement (ID 11)
09:00 - 15:30 | Author(s): Ticiana Leal
- Abstract
Abstract not provided
-
+
Session 10: Poster Discussion # 2: Metastatic Disease (ID 24)
- Event: LALCA 2019
- Type: Poster Discussion Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2019, 16:15 - 17:15, Castillo A 5-6
-
+
F10.04 - Long Term Efficacy and Safety of Ensartinib in Pre-treated Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients (eXalt2) (ID 99)
16:15 - 17:15 | Author(s): Ticiana Leal
- Abstract
Background:
Ensartinib has shown efficacy in ALK+ NSCLC patients previously treated with crizotinib and/or next generation ALK inhibitors (ALKi). This clinical benefit is associated with high intracranial (IC) activity in patients with brain metastases and a favorable safety profile. We report updated data in pre-treated NSCLC cohorts from the eXalt2 study.
Method:
eXalt2 is an ongoing multicenter Phase I/II study. We report data on patients treated with ensartinib *>*200mg PO, once daily on a continuous 28-day schedule (NCT01625234). Patients received ensartinib until disease progression, unacceptable toxicity or investigator discretion. Patients with asymptomatic brain metastases were allowed to enroll. All patients were assessed for adverse events (AEs) using CTCAE version 4.03, and response to treatment was assessed locally every 8 weeks using RECIST 1.1.
Results:
As of 20 May2019, 73 pre-treated ALK+ NSCLC response evaluable patients were assessed (Table). The median progression free survival (PFS) was 9.1 months (m) (IQR, 5.8-11.7) and 2.8 m (IQR, 1.7-5.7) respectively in post-crizotinib (n=41) and post second generation ALKi (n=32) cohorts, with 12/32 (38%) having received *>*3 lines of ALK inhibitors. Overall response rate (ORR) was 59% (uORR 66%) in the post-crizotinib cohort resulting in a disease control rate (DCR) of 95%, and ORR in the post second generation ALKi cohort was 9% (uORR 16%) resulting in a DCR of 56%. IC responses were observed in both cohorts, with an IC ORR of 50% (8/16, including 2 complete responses) and IC DCR of 100%. Safety profile of these 73 patients is similar to previously reported safety data, with rash being the most common drug-related AE (56%, mostly grades 1-2).
Conclusion:
Ensartinib is well tolerated and active in pre-treated ALK+ NSCLC patients with high DCR, remarkable intracranial efficacy and a favorable safety profile. Updated survival outcomes will be presented at the conference.
-
+
Session 8: Case Presentations and Review of Combined Modality Therapy (ID 22)
- Event: LALCA 2019
- Type: Invited Speaker Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2019, 14:15 - 15:15, Castillo A 5-6
-
+
F8.03 - Is There a Role of Neoadjuvant Therapy in NSCLC? (ID 89)
14:15 - 15:15 | Author(s): Ticiana Leal
- Abstract
Abstract not provided
-
+
OA02 - Screening and IO Toxicity (ID 2)
- Event: NACLC 2019
- Type: Oral Abstract Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 10/12/2019, 09:45 - 11:15, Imperial Ballroom (B2 Level)
-
+
OA02.04 - Discussant: Smoking Cessation and Inclusivity in Clinical Trials (ID 906)
09:45 - 11:15 | Author(s): Ticiana Leal, Ticiana Leal
- Abstract
Abstract not provided
